Analyst firms · BofA Securities · YMAB

BofA Securities YMAB price target and rating history

Y-mAbs Therapeutics Inc. (YMAB) · Health Care

BofA Securities rates Y-mAbs Therapeutics Inc. (YMAB) Underperform with a $3 price target, as of its latest action on Apr 22, 2025. It has published 3 rating actions on YMAB since December 2022, including 0 upgrades and 3 downgrades.

Current rating
Underperform
Price target
$3
Median target, all firms
Too few
Actions on YMAB
3

BofA Securities price target on YMAB

$5$4$32023202420252026
BofA Securities price target on YMAB, each point a stated target, December 2022 to April 2025.

Every BofA Securities rating on YMAB

Questions about BofA Securities and YMAB

What is BofA Securities's price target for YMAB?
BofA Securities's latest stated price target for Y-mAbs Therapeutics Inc. (YMAB) is $3, from its action on Apr 22, 2025.
What is BofA Securities's rating on YMAB?
BofA Securities rates YMAB Underperform, a bearish rating, as of Apr 22, 2025.
When did BofA Securities last change its view on YMAB?
On Apr 22, 2025, BofA Securities downgrades to Underperform from Neutral, price target $3.

More YMAB rating histories

All BofA Securities ratingsYMAB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.